Download presentation
Presentation is loading. Please wait.
Published byMarianna Chase Modified over 9 years ago
1
Proteinuria as a Surrogate Outcome in Chronic Kidney Disease Early Diabetes – Microalbuminuria (MA) Type 2 Diabetes in American Indians Robert G Nelson, MD, PhD NIDDK, Phoenix
2
Population Pima Indians from the Gila River Indian Community in Arizona Biennial examinations since 1965 of all community members ≥5 years old Medical history/physical examination –Height, weight, blood pressure –Blood and urine tests –Retinal examinations and photographs –ECG –Oral Glucose Tolerance Test Registries –ESRD –Mortality
3
Definitions Measure of Albuminuria Collection: Daytime untimed “spot” urine specimens Analyte: Urinary Albumin to Creatinine Ratio (ACR; in mg/g) Analytical methods: Albumin – immunonephelometry (Dade Behring, Inc.); Creatinine – modified Jaffe reaction (Envoy 500) Thresholds:<30 mg/g; normoalbuminuria (NA) 30-299 mg/g; microalbuminuria (MA) ≥300 mg/g; macroalbuminuria Measure of Proteinuria Collection: Daytime untimed “spot” urine specimens Analyte: Urinary Protein to Creatinine Ratio (PCR; in g/g) Analytical methods: Protein – Shevky-Stafford; Creatinine – modified Jaffe reaction (Envoy 500) Thresholds:≥0.5 g/g (or ≥1.0 g/g in some studies)
4
Age-Sex-Adjusted Death Rates in Pima Indians ≥45 Years Old Diabetes 37:1499-1504, 1988 Age-sex-duration adjusted death rate ratio 3.5 (95% CI, 2.8-4.4)
5
Prevalence of Elevated Albuminuria Diabetologia 32:870-876, 1989
6
Incidence of Proteinuria by Level of Albuminuria Baseline Participants (N) – diabetic Pima Indians ≥15 years old439 Participants with urine ACR <30 mg/g (N) ≥30 mg/g (N) 299 140 Study End Incidence rate ratio (MA/NA) of proteinuria (PCR ≥0.5g/g) [95%CI] 8.5 [4.8-15.8] Arch Intern Med 151:1761-1765, 1991 Figure. Age-sex-adjusted incidence of proteinuria in diabetic Pima Indians by albuminuria category.
7
Age-Sex-Adjusted Incidence of SCr ≥2.0 mg/dl by Duration of Diabetes and Presence of Proteinuria Kidney Int 35:681-687, 1989 Age-sex-duration adjusted incidence rate ratio 42 (95% CI, 24-75)
8
Cumulative Incidence of ESRD by Duration of Proteinuria 0 20 40 60 80 051015 Duration of Proteinuria (years) Percent Diabetologia 36:1087-1093, 1993 Whites with type 1 Pimas with type 2
9
Mean (±SE) Change in GFR According to Albuminuria at Baseline N Engl J Med 335:1636-1642, 1996
10
Sequential Measures of Albuminuria 1 st ACR measurement (ACR -1 ; prior to baseline) Participants (N) – diabetic Pima Indians ≥15 years old983 (270 with MA) Urine ACR [median, 25 th and 75 th percentiles] 21 [11-67] 2 nd ACR measurement within 6 years (ACR 0 ; baseline) Participants (N)983 Urine ACR [median, 25 th and 75 th percentiles] 27 [13-121] Early change (Remission to NA <30 mg/g) (N)65 (24%) Study End Incidence of ESRD for each doubling of ACR 0 [95%CI] 1.7 [1.5-1.9] Death rate from natural mortality for each doubling of ACR 0 [95%CI] 1.2 [1.1-1.3] Am J Kidney Dis 51:759-766, 2008
11
Changes in ACR Categories Between Two ACR Measurements Taken Within a 6-year Period ACR 0 <30 mg/g30-300 mg/g300-3000 mg/g≥ 3000 mg/gTotal <30 mg/g 460 (76.5%) 129 (21.5%)11 (1.8%)1 (0.2%)601 ACR -1 30-300 mg/g65 (24.1%) 155 (57.4%) 45 (16.7%)5 (1.8%)270 300-3000 mg/g2 (2.2%)12 (13.0%) 46 (50.0%) 32 (34.8%)92 ≥ 3000 mg/g01 (5.0%)2 (10.0%) 17 (85.0%) 20 Total52729710455983 Am J Kidney Dis 51:759-766, 2008
12
Incidence Rate Ratio for Diabetic ESRD (N=89 cases) Relative to Persistently Normal ACR Am J Kidney Dis 51:759-766, 2008 ACR 0 NormalMicroMacro Normal13.1 (1.2-7.7)24.9 (7.5-82.9) ACR -1 Micro1.9 (0.4-8.7)4.5 (2.0-10.6)20.5 (9.1-46.1) Macro03.8 (0.8-17.8)15.4 (6.6-35.1)
13
Incidence of Diabetic ESRD Kidney Int 70:1840-1846, 2006
14
Summary MA occurs frequently in type 2 diabetes MA predicts development of overt nephropathy MA frequently regresses to normoalbuminuria Low current ACR is associated with a good prognosis regardless of earlier values Proteinuria strongly predicts progression to renal insufficiency, ESRD, and death Distribution of albuminuria is changing over time
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.